By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


PTC Therapeutics, Inc. 

100 Corporate Court

South Plainfield  New Jersey  07080-2449  U.S.A.
Phone: 908-222-7000 Fax: 908-222-7231


Drug Discovery

Company News
PTC Therapeutics (PTCT) To Participate At Upcoming Investor Conferences 1/29/2016 7:21:36 AM
PTC Therapeutics (PTCT) Outlines Business Priorities For The Development And Commercialization Of Translarna And Progress Of The Company Pipeline 1/11/2016 8:12:15 AM
PTC Therapeutics (PTCT) Completes Rolling NDA Submission To FDA And Submits Phase 3 ACT DMD Clinical Trial Results To European Medicines Agency for Translarna (ataluren) For Treatment Of Nonsense Mutation Duchenne Muscular Dystrophy 1/8/2016 6:23:39 AM
PTC Therapeutics (PTCT) Release: Spinal Muscular Atrophy Program Advances With Additional Product Candidate Entering Clinical Development 1/7/2016 2:06:58 PM
PTC Therapeutics (PTCT) Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 1/7/2016 7:01:55 AM
PTC Therapeutics (PTCT) To Present At The 34th Annual J.P. Morgan Healthcare Conference 12/28/2015 7:58:06 AM
PTC Therapeutics (PTCT) And Massachusetts General Hospital Collaborate On Rare Disease Research 12/9/2015 7:27:33 AM
PTC Therapeutics (PTCT) Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 12/7/2015 8:49:46 AM
PTC Therapeutics (PTCT) Completes Enrollment Of Phase 3 Clinical Trial Of Translarna For Patients With Cystic Fibrosis 11/19/2015 6:15:58 AM
PTC Therapeutics (PTCT) Reports Third Quarter 2015 Financial Results, Provides Corporate Update And Reviews Key Findings From ACT DMD 11/10/2015 8:13:49 AM